Breath of life: new test could sniff out gut cancers before they spread
NCT ID NCT07714538
First seen Jul 20, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants provide a breath sample before a scheduled hospital procedure, and researchers check whether the test can reliably tell who has cancer and who does not.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a breath test measuring volatile organic compounds (VOCs)
- What this could lead to
- If successful, this breath test could enable earlier detection of gastrointestinal cancers, potentially improving treatment outcomes and survival.
- What could go wrong
- This is a validation study; the test may not prove accurate enough for clinical use, and false positives or negatives could occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult Participants who meet the eligibility criteria and are being referred for further specialised investigations within the NHS.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adult participants ≥ 18 years old who meet at least one of the following criteria Colorectal arm: 1. Cancer: Histologically-confirmed CRC\* 2. Control: Non-specific abdominal symptoms with normal or benign colonoscopy findings Pancreatic arm: 1. Cancer: Histologically-confirmed PDAC\* 2. Control: Non-specific abdominal symptoms with a radiologically-normal pancreas Oesophagogastric arm: 1. Cancer: Histologically-confirmed OGC\* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Oesophageal squamous arm: 1. Cancer: Histologically-confirmed OSCC\* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Liver arm: 1. Cancer: Histologically- or radiologically-confirmed HCC or CCC\* 2. Control: Non-specific abdominal symptoms with a radiologically-normal liver * Patients with suspected cancer (e.g. based on imaging) but who do not have histological confirmation prior to participating in the study may still be recruited and followed up to determine whether or not a diagnosis of cancer was subsequently confirmed. Exclusion Criteria: * Patients who have already received chemotherapy, radiotherapy or surgery for their cancer * History of another cancer (other than non-melanoma skin cancers) within three years * Participants with co-morbidities preventing breath collection * Unable or unwilling to provide informed consent * (For Oesophagogastric arm only): Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid * (For Colorectal arm only): Participants receiving bowel prep in the previous 7 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0NN, United Kingdom
-
Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, L7 8XP, United Kingdom
-
Maidstone and Tunbridge Wells NHS Trust
Maidstone, Kent, ME16 9QQ, United Kingdom
-
NHS Greater Glasgow and Clyde
Glasgow, G12 0XH, United Kingdom
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, L7 8YA, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phase 2, randomized, open-label study of VVD-133214 in COmbination with pembrolizumab compared to pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)
- Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma
- A phase II/III randomized clinical trial of CisPlatin plUs gemcitabine and nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
- Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
- AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?
- Can a smart drug outsmart pancreatic cancer?